These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27233747)

  • 1. Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.
    Yi X; Wang Y; Lin J; Cheng W; Zhou Q; Wang C
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):761-768. PubMed ID: 27233747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel.
    Yi X; Zhou Q; Zhang Y; Zhou J; Lin J
    BMC Neurol; 2020 Apr; 20(1):159. PubMed ID: 32345264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
    Yi X; Lin J; Wang Y; Zhou Q; Wang C; Cheng W; Chi L
    J Atheroscler Thromb; 2016 Oct; 23(10):1188-1200. PubMed ID: 26961113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet receptor Gene (P2Y12, P2Y1) and platelet glycoprotein Gene (GPIIIa) polymorphisms are associated with antiplatelet drug responsiveness and clinical outcomes after acute minor ischemic stroke.
    Yi X; Zhou Q; Wang C; Lin J; Liu P; Fu C
    Eur J Clin Pharmacol; 2017 Apr; 73(4):437-443. PubMed ID: 28091702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
    Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
    CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
    Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
    Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness.
    Ou W; He Y; Li A; Liu B; Jin L
    Int Heart J; 2016 Sep; 57(5):586-92. PubMed ID: 27488401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
    Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
    J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
    Liu R; Zhou ZY; Chen YB; Li JL; Yu WB; Chen XM; Zhao M; Zhao YQ; Cai YF; Jin J; Huang M
    Acta Pharmacol Sin; 2016 Jul; 37(7):882-8. PubMed ID: 27133299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
    Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
    Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
    Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
    J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
    Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
    Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
    Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R
    Platelets; 2013; 24(4):297-302. PubMed ID: 22721490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.
    Shalia KK; Shah VK; Pawar P; Divekar SS; Payannavar S
    Indian Heart J; 2013; 65(2):158-67. PubMed ID: 23647895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study.
    Joo HJ; Ahn SG; Park JH; Park JY; Hong SJ; Kim SY; Choi W; Gwon H; Lim YH; Kim W; Kang WC; Cho YH; Kim YH; Yoon J; Shin W; Hong MK; Garg S; Jang Y; Lim DS
    Sci Rep; 2018 Jan; 8(1):1229. PubMed ID: 29352151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2.
    Yi X; Han Z; Zhou Q; Cheng W; Lin J; Wang C
    Clin Appl Thromb Hemost; 2018 Jan; 24(1):55-62. PubMed ID: 27637911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.